← Back to patent-cliff list
Iron Isomaltoside
Tier C — Watch / tradeIron Isomaltoside
Pharmacosmos A/S
Originator
2016
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Brand：Isofer, Monoferric, Diafer, Jilazo, Mono ver, Monofer, Monover
Indications (approved)：Iron deficiency anaemia
Regional status
US
Approved
2020-01-16
EU
No progress
2007-05-01
China
Approved
2021-01-30
Japan
Approved
2022-03-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Iron Isomaltoside?
Approved indications include: Iron deficiency anaemia.
When does the Iron Isomaltoside patent expire?
No public expiry year is available for Iron Isomaltoside yet; this page updates once verified.
How do I get a quote for Iron Isomaltoside intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29